Transforming lives through a novel treatment for NASH
TamuroBio is singularly focused on the expedient development and delivery of a first-in-class treatment of non-alcoholic steatohepatitis (NASH)
TamuroBio is an early-stage biotech company with a mission to transform the lives of patients suffering from NASH, an area of unmet need as there are currently no approved therapeutics for this disease worldwide.
TB-019 is an innovative multi-pathway approach to a prevalent metabolic disease, NASH. TB-019 has demonstrated activity in both prevention and treatment modes in relevant pre-clinical studies.